Retatrutide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material

Retatrutide (LY3437943) acetate is a triple agonist peptide for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. It exhibits activity on mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191, and 0.794 nM, respectively.

In vivo, Retatrutide (LY3437943) acetate engages with GCGR and enhances glucose tolerance in an ipGTT by acting through GIP or GLP-1 receptors. Activation via the glucagon receptor by Retatrutide acetate leads to significant weight reduction and increased energy expenditure. Retatrutide acetate can be utilized in research related to obesity.

Q1: May I get one sample before placing order?

Re: Yes, Sample are available. For normal products, samples are for free and you just need to bear the freight; For those high value products, you just need to freight and certain product cost. When we both cooperate for some times or when you are our VIP customer, free sample will be offered when you need.

Q2: Which payment is available for your company?

Re: T/T, PayPal,bank transfer etc. You can choose the one which is convenient for you.

Q3: How and when can I get my goods after payment?

Re: For small quantity products, they will be delivered to you by international courier(DHL, FedEx, TNT etc.) or by air. Usually it will cost 5-7days that you can get the goods after delivery.For large quantity products, shipping by see is worthwhile.It will cost 15 to 30 days to come to your destination port, which depends on where the port is.

Q4: Is there any possible to use my appointed label or package?

Re: Yes. If needed, we'd like to that.

Hangzhou Thinheal Pharma-Tech Co., Ltd. was established in 2019. It is a biopharmaceutical company that combines independent R&D, production, sales and customized research and development and production of peptide products. The core management team is composed of professionals with a pharmaceutical background and nearly 20 years of management experience in the peptide industry. Thinheal has built a R&D center and a production base. The total production capacity of chemically synthesized peptides has now reached several tons, ranking at the forefront of the industry.

The company has a complete and efficient peptide R&D, production and sales system, and provides a full range of peptide industrialization services, including peptide API R&D and production business, peptide customized R&D and production (CDMO) business, and beauty peptide research and development and production business. The company's revenue is mainly from peptide API business. Peptide API products mainly include more than 20 varieties such as semaglutide, tirzepatide, liraglutide, etc., among which semaglutide, tirzepatide and other varieties have completed the US FDA DMF filing. The CDMO business includes project-based entrusted research and development, entrusted production and sales. The main customers of the CDMO business are innovative drug companies and scientific research institutions, among which some pharmaceutical companies have cooperated with Thinheal since the product development stage and have established a solid cooperative relationship.